Sensible Medical Innovations News
9 articles
/PRNewswire/ -- Sensible Medical today announced that its ReDS™ Pro System has been contracted for inclusion in the Federal Supply Schedule (FSS), making it...
Sensible Medical has announced that its ReDS™ Pro System has been included in the Federal Supply Schedule (FSS), facilitating its purchase by VA Medical Centers and other federal healthcare facilities across the U.S. The ReDS™ Pro System is a non-invasive device designed to measure lung fluid volume, aiding clinicians in managing heart failure and other conditions. With FSS approval, VA facilities can procure the system under pre-negotiated terms, enhancing access for veterans. The ReDS System is applicable in various care settings and has FDA 510(k) clearance and a CE mark. Sensible Medical aims to improve heart failure patient care through innovative solutions.
Product StageCustomers
Sensible Medical Sold Covid-19 Patient Monitoring Systems to Hospitals in Italy, U.S., Says CEO
Sensible Medical Innovation Ltd., an Israel-based medtech company, has developed a radar-based system that can continuously monitor lung fluid levels in coronavirus patients. The system offers real-time insights on any deterioration in the patients status, providing vital information for immediate care. The radar technology used by the system can be used through clothes and for long periods of time, unlike a CT scan. Four hospitals in Italy have already acquired the system, with a U.S. hospital purchasing 20 units. Sensible Medical counts Boston Scientific Corp., Shanghai Longtech Precision Machinery Co. Ltd., and Genesis Partners among its backers.
CustomersPartners
Sensible Medical Innovations Licenses ReDS™ Technology to Bayer
Sensible Medical Innovations and Bayer have signed an agreement, making Bayer Sensibles largest customer in Europe. Bayer will use Sensible ReDS™ technology as a biomarker to monitor lung congestion in a clinical trial. Sensibles ReDS System is a wearable vest that quantifies lung fluid non-invasively. The technology is primarily being commercialized in the US, but this agreement is a major step forward in the European market. Sensible Medical Innovations aims to develop a new standard of care in lung fluid management.
Customers
Medicure invests $10M Sensible Medical to market ReDS
The Indian Bio & Health Sciences Industry awards, known as the BioSpectrum Excellence Awards, were held on June 30, 2023. The awards honor the achievements of industry leaders in the Indian Bio & Health Sciences Industry. The event is highly anticipated in the industry.
None
Ohio State Studies If High-tech Vest Can Help Manage Heart Failure at Home
Doctors at The Ohio State University Richard M. Ross Heart Hospital are testing a high-tech vest that measures fluid inside the lungs to prevent repeated hospital trips for heart failure patients. The SensiVest, created by Sensible Medical, uses radar technology to accurately measure water inside the lungs. The vest is being tested in a national clinical trial to determine its effectiveness in monitoring and managing lung fluid, reducing hospitalizations, and improving quality of life. A previous study showed an 87 percent reduction in heart failure hospitalizations with the use of the vest. Patients in the trial will be followed for up to nine months.
Customers
Groundbreaking Use of Radar-Equipped Vests in a Hospital Promises to Improve the Care of Heart Failure Patients
Sensible Medical Innovations Receives FDA 510K Clearance for its Non-Invasive Thoracic Fluid Status Monitor
Sensible Medical Innovations has received clearance from the FDA for its non-invasive thoracic fluid status monitor. The product, powered by ReDS medical radar technology, allows patients to measure their lung fluid content at home and upload the results to a secure cloud application for healthcare professionals to review. This technology aims to improve the quality of life for patients with fluid management problems and reduce hospital readmissions. Sensible Medical Innovations is excited to enter the US market with this solution.
Customers
Sensible Medical Innovations Ltd. opening first U.S. office in Columbus, Ohio
Sensible Medical Innovations, an Israeli company developing a non-invasive device for monitoring congestive heart failure patients, is opening its first U.S. office. The company received a $7 million investment from venture firms SPC Vitalife and Genesis Partners. Sensible Medical aims to replace exploratory surgery with its imaging device, which has been tested in animals and is preparing for human trials. The company plans to work with Ohio State University and the Cleveland Clinic for testing and expects to hire more employees in Ohio.
InvestmentExpand
Israeli CHF company Sensible Medical Innovations raises $7m
Israeli company Sensible Medical Innovations has raised $7 million in a fund raising round led by Genesis and Vitalife funds. The company is developing a non-invasive device for monitoring congestive heart failure and has developed an imaging method for internal organs based on IT technology. Sensible Medicals product has been successfully tested on animals and will now go forward to human trials.
Investment
